China Resources Sanjiu Medical & Pharmaceutical (SHE:000999) recorded an 18% rise in attributable profit for 2024 to 3.37 billion yuan from 2.85 billion yuan a year prior, a Wednesday filing by parent China Resources Pharmaceutical Group (HKG:3320) with the Hong Kong bourse said.
Earnings per share were 2.63 yuan in the year, up from 2.23 yuan in the last fiscal year.
The drug company's revenue rose by 12% to 27.6 billion yuan in the period from 24.7 billion yuan a year prior.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.